A pill form of weight-loss drug Wegovy, manufactured by Danish drugmaker Novo Nordisk, is now available in the U.S., giving Americans access to an oral medication to treat obesity. The starting dose ...

Novo Nordisk has won the race to secure approval from the U.S. Food and Drug Administration for the first weight-loss drug to be administered orally. Jules Rimmer is a markets reporter in ...

Danish drugmaker Novo Nordisk A/S was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat diabetes, could help trim their ...

Novo Nordisk noted the drug will be available in early January Novo Nordisk A/S (NYSE:NVO) stock is up 8.8% to trade at $52.37 at last check, after the biopharmaceutical giant received approval from ...

The pole position in the GLP-1 weight loss space is currently held by Eli Lilly. Novo Nordisk was the early leader, showing that being first doesn't always mean you stay at the head of the pack.

Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...

As both Novo Nordisk and Eli Lilly race to develop their long-anticipated oral GLP-1 obesity meds, a new report shows one taking a clear lead among potential prescribers. Spherix Global Insights ...

When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...

Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026. Novo ...

Novo Nordisk remains a Strong Buy despite recent earnings misses, trial setbacks, and competitive pressures in the weight loss/diabetes market. NVO's valuation is compelling, trading at a low P/E of ...

CHONGQING, CHINA - SEPTEMBER 10: In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. The maker of Wegovy and Ozempic, ...

Septerna, Inc. delivered a strong 3Q25, driven by partnership revenue from its transformative collaboration with Novo Nordisk. SEPN's Novo partnership brings $195M upfront, a potential $2.2B in ...